Brenipatide (LY-3537031) is an investigational dual GLP-1/GIP peptide from Eli Lilly, designed for a long half-life. Its lead Phase 3 trials target alcohol use disorder and depression, not obesity. It is not FDA-approved and not available to buy, compound, or prescribe today.
Brenipatide is not FDA-approved for any use. Eli Lilly is studying it in clinical trials — most prominently Phase 3 programs in alcohol use disorder and major depressive disorder. It isn't sold through pharmacies, compounders, or peptide suppliers.
This summary is based on public company disclosures, the ClinicalTrials.gov registry, and published research — it isn't an official FDA determination, and no efficacy results have been published yet.
As of October 24, 2026, we found no public report of an FDA expedited-program designation (such as Breakthrough or Fast Track) or of a meeting outcome for brenipatide. Sponsors don't always disclose such interactions, so that is not proof none has occurred.
Brenipatide is an investigational medicine from Eli Lilly, developed under the code name LY-3537031. It's a dual agonist of the GLP-1 and GIP receptors — the same two targets as tirzepatide — but designed for a long half-life so it can be dosed less often. It's still in clinical trials and has not been approved by the FDA.
This page explains what brenipatide is, what it's being studied for, how it's thought to work, and exactly where it stands with regulators. It's written to help people understand the drug — not to sell it, and not as medical advice.
The list below is what brenipatide is being studied for in clinical trials — not uses the FDA has approved. No efficacy results have been published yet, so this describes the research program, not a proven effect.
None of these uses is FDA-approved. Conditions like alcohol use disorder, depression, and IBS need care from a licensed professional — not a self-directed peptide.
By activating both the GLP-1 and GIP receptors, brenipatide is expected to work the way tirzepatide does: helping the body release insulin only when blood sugar is high, easing digestion, and reducing appetite. Hitting both receptors together is thought to produce a bigger effect than either one alone. 8
Its neuroscience trials rest on a different piece of the same biology: GLP-1 signaling in the brain appears to quiet reward and craving circuits, the proposed link to reduced drinking and other cravings. This is a working theory under investigation — not a result Lilly has published for brenipatide specifically.
In its trials, brenipatide is injected under the skin. The dosing schedule in the Phase 3 trials is set by Lilly's protocols and isn't stated in the registry; in Phase 1, a half-life of about 9–12 days supported weekly maintenance dosing.
It isn't FDA-approved, so there's no dosing guidance to give here. It's only available inside Lilly's clinical trials, where dose and schedule are set by the trial protocol, not by the person taking it.
Topline data from the lead Phase 3 trials is expected in early 2028.7 A filing and FDA decision would follow, so we estimate 2029 at the earliest, assuming the trials succeed. Lilly has not announced a filing timeline.
Status as listed on ClinicalTrials.gov on October 24, 2026; all trials are sponsored by Eli Lilly. Phase 1 studies are not shown.
"Compounded" drugs aren't approved by the FDA — a pharmacy or outsourcing facility prepares them instead of the manufacturer, under one of two legal pathways.
After tirzepatide (Lilly's Mounjaro/Zepbound) was approved, a supply shortage — added to FDA's shortage list in December 2022 — opened the door for 503A pharmacies to legally compound copies, and a wave of 503B facilities and telehealth clinics followed.5
That window closed once supply caught up: FDA declared the tirzepatide shortage resolved in October 2024 and ended 503B enforcement discretion for it in March 2025.4 On April 30, 2026, FDA proposed excluding tirzepatide, semaglutide and liraglutide from the 503B bulks list; comments closed June 29, 2026, and we found no final action as of October 24, 2026.6
Anything sold online today as "brenipatide" for research or personal use is unauthorized, unregulated, and not verified to be the same molecule studied in Lilly's trials.